HealthLynked Reports Annual Revenue Growth of 53% and Net

New Post Public Reply Private Reply Replies (0) Message Board
LocWolf
361
HealthLynked Reports Annual Revenue Growth of 53% and Net Equity Improvement of $4.2M to $1.35M

April 01 2021 - 08:00AM

HealthLynked Reports Annual Revenue Growth of 53% and Net Equity Improvement of $4.2M to $1.35M

Naples, FL -- April 1, 2021 -- InvestorsHub NewsWire -- HealthLynked Corp. (OTCQB: HLYK), a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients and medical data, late yesterday reported its financial results for the quarter and year ended December 31, 2020, the company reported a 53% annual revenue growth and net shareholders' equity improvement of $4.2 million. The company improved from a negative $2.8 million net equity at the end of 2019 to positive net equity of $1.35 million at year-end 2020.



Fourth Quarter 2020 Compared to Fourth Quarter 2019:

36% increase in revenue in Q4'20 compared to Q4'19, increasing to $1,594,515 from $1,172,877 in Q4'19

Net equity of $1,350,008 in Q4'20 compared to ($2,842,680) in Q4 2019, an improvement of $4,192,688.

Operating loss increased 21% from $871,882 in Q4'19 to $1,051,103 in Q4'20

Net loss decreased by 22% from $2,463,028 in Q4'19 to $1,922,897 in Q4'20

Patient appointments decreased 11% from 4,006 in Q4'19 to 3,564 in Q4'20

Time of Service collections improved 29% from $777,895 in Q4'19 to $1,001,312 in Q4'20

Full Year 2020 Compared to 2019:

53% increase in revenue to $6,133,120 in 2020 compared to $4,018,818 in 2019

Operating loss decreased by 4% from $3,209,010 in 2019 to $3,071,829 in 2020

Patient appointments decreased 11% from 16,409 in 2019 to 14,628 in 2020

Time of Service collections increased 45% from $2,475,377 in 2019 to $3,589,601 in 2020

"Our 10-K concludes a very successful year for HealthLynked with 53% growth annually and 36% over same quarter last year." said Michael Dent M.D., the Company's Chairman and CEO. "We made significant improvements in our balance sheet, increasing the company's net equity by $4.2 million in 2020. The positive trend has continued into 2021 and we expect our first quarter net equity to be approximately $8 million, a projected $6.7 million improvement since the end of 2020."

Dr. Dent went on to say, "We are very excited about our recent Healthcare Summit held at the Arthrex Campus from March 15-17th in Naples, Florida. The event hosted thought leaders from around the world who presented on the latest trends in healthcare. DocLynk, our Telemedicine service, is on schedule to launch this month. Other exciting products are scheduled to launch in 2021. We have seen the number of HealthLynked users grow significantly since COVID-19, with over 6 million downloads, and with our new services we expect to see new revenues from these efforts during 2021."

George O'Leary, HealthLynked Chief Financial Officer, said "We are very proud of the work we have done to improve our net equity over the last 15 months, and with approximately $8 million in net equity estimated by the end of first quarter 2021, we believe HealthLynked is in a great position for our planned uplisting during 2021."

Healthlynked Corp (HLYK) Stock Research Links

HLYK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 59

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 80

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 299

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 242

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading